Pharmaceutical Product Development Form 3/A Science 37 / Holding Co Jaguar II ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC

(Last)

(First)

(Middle)

929 NORTH FRONT STREET

(Street)

WILMINGTON

28401

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/06/2021

3. Issuer Name and Ticker or Trading Symbol
Science 37 Holdings, Inc. [ SNCE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)
10/18/2021

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	17,379,797	D⁽¹⁾⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

1. Name and Address of Reporting Person^*

PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC

(Last)

(First)

(Middle)

929 NORTH FRONT STREET

(Street)

WILMINGTON

28401

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Wildcat Acquisition Holdings (UK) Ltd

(Last)

(First)

(Middle)

929 NORTH FRONT STREET

(Street)

WILMINGTON

28401

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Jaguar Holding Co II

(Last)

(First)

(Middle)

929 NORTH FRONT STREET

(Street)

WILMINGTON

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Jaguar Holding Co I, LLC

(Last)

(First)

(Middle)

929 NORTH FRONT STREET

(Street)

WILMINGTON

28401

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Eagle Holding Co II, LLC

(Last)

(First)

(Middle)

929 NORTH FRONT STREET

(Street)

WILMINGTON

28401

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

PPD, Inc.

(Last)

(First)

(Middle)

929 NORTH FRONT STREET

(Street)

WILMINGTON

28401

(City)

(State)

(Zip)

Explanation of Responses:

1. These shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. are held of record by Pharmaceutical Product Development, LLC ("Pharma LLC"). Wildcat Acquisition Holdings (UK) Limited ("Wildcat") is the sole member of Pharma LLC; Jaguar Holding Company II ("Jaguar II") is the sole shareholder of Wildcat; Jaguar Holding Company I, LLC ("Jaguar I") is the sole shareholder of Jaguar II; Eagle Holding Company II, LLC ("Eagle II") is the sole member of Jaguar I; and PPD, Inc. is the sole member of Eagle II. By virtue of such relationships, each of the reporting persons may be deemed to have beneficial ownership over such shares of common stock.

2. This report on Form 3/A is jointly filed by the reporting persons. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein.

Remarks:

This Form 3/A amends and restates the original Form 3 filed by the Reporting Persons on October 18, 2021 (the "Original Form 3"). This amendment is being filed to correct the number of securities reported as beneficially owned by the Reporting Persons in the Original Form 3.

	Jaguar Holding Company II By: /s/ Julia James, Name: Julia James, Title: General Counsel and Secretary	11/08/2021
	Eagle Holding Company II, LLC, By: /s/ B. Judd Harman, Name: B. Judd Hartman, Title: General Counsel and Secretary	11/08/2021
	Pharmaceutical Product Development, LLC By: /s/ Julia James, Name: Julia James, Title: EVP, General Counsel and Secretary	11/08/2021
	Jaguar Holding Company I, LLC By: Eagle Holding Company II, LLC, By: /s/ B. Judd Harman, Name: B. Judd Hartman, Title: General Counsel and Secretary	11/08/2021
	Wildcat Acquisition Holdings (UK) Limited By: /s/ B. Judd Hartman, Name: B. Judd Hartman, Title: Director	11/08/2021
	PPD, Inc. By: /s/ Julia James, Name: Julia James, Title: EVP, General Counsel and Secretary	11/08/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Pharmaceutical Product Development (PPDI) Form 3/AScience 37 / Holding Co Jaguar II ownership change